Treatment interruption for convenience, cost cutting and toxicity sparing

Area of Science:

• Infectious Diseases
• Pharmacology
• Immunology

Background:

• Scheduled treatment interruption (STI) is explored as an alternative to continuous antiretroviral therapy (ART) to mitigate side effects, reduce costs, and enhance patient comfort.
• Concerns exist regarding the safety of STI, including the potential for drug resistance, treatment failure, and disease progression due to declining CD4 cell counts or virological rebound.

Purpose of the Study:

• To evaluate the safety and efficacy of scheduled treatment interruption strategies compared to continuous antiretroviral treatment.
• To assess the impact of STI on drug exposure, toxicity, quality of life, and virological/immunological parameters in HIV management.

Main Methods:

• Review of randomized controlled trials evaluating fixed-cycle STI and CD4 cell-guided STI.
• Analysis of data on drug exposure, toxicity, quality of life, CD4 cell counts, and viral load.

Main Results:

• STI, particularly CD4 cell-guided, significantly reduces overall drug exposure by approximately 60%.
• Contrary to expectations, most trials indicate minimal reduction in drug-related toxicity and no significant improvement in quality of life.
• HIV progression and drug resistance have been observed in some studies utilizing STI.

Conclusions:

• While STI reduces costs, its effects on toxicity and quality of life are inconclusive.
• Due to reported HIV progression and resistance, STI cannot be recommended over continuous ART.
• Specific interruption protocols (e.g., CD4 count >350 cells/µL, duration <3 months, drug properties considered) may be safe for select patients.